Azilsartan: Current Evidence and Perspectives in Management of Hypertension

Figures

• 

  Figure 1. Drugs acting on renin angiotensin aldosterone system. ACE, angiotensin-converting enzyme; ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DRI, direct renin inhibitor; MRA, mineralocorticoid receptor antagonist; and AT1, angiotensin 1.

• 

  Figure 2. Milestones of development of various ARB's. Eprosartan was another ARB developed in 1992 by Glaxo Smithkline but not marketed in our country though approved by USFDA; losartan got USFDA approval only in 1995.

• 

  Figure 3. Head-to-head comparison of azilsartan and other RAAS blockers in clinical studies for reduction in 24-hour mean systolic blood pressure (SBP, as measured by ambulatory BP monitoring) from baseline. RAAS blockers used as a comparator arm in various studies were as follows: White et al., valsartan 320 mg (purple bar) and olmesartan 40 mg (green bar); Bonner et al., ramipril 10 mg; Bakris et al., olmesartan 40 mg; Sica et al., valsartan 320 mg; Rakugi et al., candesartan.

• 

  Figure 4. Clinical studies of head-to-head comparison of combination therapy with azilsartan for reduction in mean systolic blood pressure from the baseline. ∗24-hour systolic BP measured by ABPM; ∗∗clinic systolic BP used; AZT, azilsartan; CLT, chlorthalidone; HCTZ, hydrochlorothiazide; and OLM, olmesartan.

• 

  Figure 5. Take home messages.